A multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE

Grants and Contracts Details

StatusActive
Effective start/end date3/23/222/14/25

Funding

  • Anthos Therapeutics Incorporated: $116,496.00